ERBB2 and breast carcinoma: This potentially aligns with responses to atezolizumab and pembrolizumab immunotherapy in metastatic TNBC patients.43 Our similar observation of an association between HER2 breast cancers and the inflammatory heterocellular subtype suggests that some HER2-positive patients may similarly be eligible for immunotherapy.